Literature DB >> 25868799

Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis.

Hui Chen1, Xinchen Xu1, Min Liu2, Wen Zhang3, Hua-zhu Ke2, An Qin4, Tingting Tang5, Eryi Lu6.   

Abstract

INTRODUCTION: Periodontitis and osteoporosis are bone destructive diseases with a high prevalence in the adult population. The concomitant presence of osteoporosis may be a risk factor of progression of periodontal destruction. We studied the effect of sclerostin-neutralizing monoclonal antibody (Scl-Ab) on alveolar bone endpoints in an ovariectomized (OVX) rat model of induced experimental periodontitis.
METHODS: Sixty female, 4-month-old Sprague-Dawley rats underwent sham operation or bilateral OVX and were left untreated for 2 months. Experimental periodontitis (ligature) was established by placing silk sutures subgingival to the right maxillary first and second molar teeth for 4 weeks, and feeding the rats food and high-sugar drinking water during this period. Thereafter, ligatures were removed and 25mg/kg vehicle or Scl-Ab was administered subcutaneously twice weekly for 6 weeks. Rats were randomized into four groups: (1) Control (Sham+Vehicle), (2) Sham+Ligature+Vehicle, (3) OVX+Ligature+Vehicle, and (4) OVX + Ligature + Scl-Ab. Terminal blood and right maxilla specimens were collected for analyses.
RESULTS: Group 3 rats showed lower bone volume fraction (BVF) of alveolar bone with higher bone resorption and lower bone formation than Group 2 rats. Group 4 rats had higher alveolar crest height, as assessed by linear distance of cementoenamel junction to the alveolar bone crest and greater alveolar bone mass using Micro CT, than Group 3 rats. Significantly higher values of mineral apposition rate (MAR) and mineralizing surface/bone surface (MS/BS) were also observed in Group 4 rats by analyzing polychrome sequential labeling data. Increased serum osteocalcin and osteoprotegerin, and deceased serum tartrate-resistant acid phosphatase and CTx-1 illustrate the ability of Scl-Ab to increase alveolar bone mass by enhancing bone formation and decreasing bone resorption in an animal model of estrogen deficiency osteopenia plus periodontitis.
CONCLUSION: Scl-Ab could be a potential bone anabolic agent for improving alveolar crest height and higher alveolar bone mass in conditions where alveolar bone loss in periodontitis is compounded by estrogen deficiency osteopenia.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone anabolic agent; Estrogen deficiency osteopenia; Periodontitis; Sclerostin antibody

Mesh:

Substances:

Year:  2015        PMID: 25868799     DOI: 10.1016/j.bone.2015.04.002

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  15 in total

1.  Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation.

Authors:  Matthew Tamplen; Tristan Fowler; Jeffery Markey; P Daniel Knott; Larry J Suva; Tamara Alliston
Journal:  Head Neck       Date:  2018-03-09       Impact factor: 3.147

2.  Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse.

Authors:  Dongye Zhang; Minyi Hu; Timothy Chu; Liangjun Lin; Jingyu Wang; Xiaodong Li; Hua Zhu Ke; Yi-Xian Qin
Journal:  Bone       Date:  2016-02-08       Impact factor: 4.398

Review 3.  Application of anti-Sclerostin therapy in non-osteoporosis disease models.

Authors:  Christina M Jacobsen
Journal:  Bone       Date:  2016-10-22       Impact factor: 4.398

Review 4.  Osteoporosis and periodontal diseases - An update on their association and mechanistic links.

Authors:  Bo Yu; Cun-Yu Wang
Journal:  Periodontol 2000       Date:  2022-03-04       Impact factor: 12.239

5.  Clinically Relevant Doses of Sclerostin Antibody Do Not Induce Osteonecrosis of the Jaw (ONJ) in Rats with Experimental Periodontitis.

Authors:  Danny Hadaya; Ioannis Gkouveris; Akrivoula Soundia; Olga Bezouglaia; Rogely W Boyce; Marina Stolina; Denise Dwyer; Sarah M Dry; Flavia Q Pirih; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2018-09-24       Impact factor: 6.741

6.  Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury.

Authors:  Wei Zhao; Xiaodong Li; Yuanzhen Peng; Yiwen Qin; Jiangping Pan; Jiliang Li; Aihua Xu; Michael S Ominsky; Christopher Cardozo; Jian Q Feng; Hua Zhu Ke; William A Bauman; Weiping Qin
Journal:  Calcif Tissue Int       Date:  2018-06-21       Impact factor: 4.333

7.  Hyperglycemia increases the expression levels of sclerostin in a reactive oxygen species- and tumor necrosis factor-alpha-dependent manner.

Authors:  Jiho Kang; Kanitsak Boonanantanasarn; Kyunghwa Baek; Kyung Mi Woo; Hyun-Mo Ryoo; Jeong-Hwa Baek; Gwan-Shik Kim
Journal:  J Periodontal Implant Sci       Date:  2015-06-08       Impact factor: 2.614

8.  Antibody-Mediated Osseous Regeneration for Bone Tissue Engineering in Canine Segmental Defects.

Authors:  A Khojasteh; S Hosseinpour; M M Dehghan; F Mashhadiabbas; M Rezai Rad; S Ansari; S Farzad Mohajeri; H H Zadeh
Journal:  Biomed Res Int       Date:  2018-02-28       Impact factor: 3.411

Review 9.  Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges.

Authors:  Claire MacNabb; D Patton; J S Hayes
Journal:  J Osteoporos       Date:  2016-05-26

10.  Intermittent PTH administration improves alveolar bone formation in type 1 diabetic rats with periodontitis.

Authors:  Ji-Hye Kim; Ae Ri Kim; Yun Hui Choi; Aeryun Kim; Yongsung Sohn; Gye-Hyeong Woo; Jeong-Heon Cha; Eun-Jung Bak; Yun-Jung Yoo
Journal:  J Transl Med       Date:  2018-03-15       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.